Patents by Inventor Manuel Baca
Manuel Baca has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8613925Abstract: Antibody antagonists of human interleukin-13 receptor alpha 1 which bind to hIL-13R?1 through domain 3 of the extracellular region of the receptor and inhibit IL-13 receptor-mediated signaling by IL-13 are disclosed herein. These antibodies have uses inter alia in the treatment or prevention of IL-13-related disorders and diseases. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing hIL-13R?1-mediated activities are also disclosed.Type: GrantFiled: October 19, 2007Date of Patent: December 24, 2013Assignee: CSL LimitedInventors: Andrew Donald Nash, Manuel Baca, Louis Jerry Fabri, Dennis Zaller, William R. Strohl, Zhiqiang An
-
Patent number: 8568722Abstract: High affinity antibody antagonists of human interleukin-13 receptor alpha 1 are disclosed. The antibody molecules are effective in the inhibition of IL-13R?1-mediated activities and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with hIL-13R?1 activity. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing IL-13R?1-mediated activities are also disclosed.Type: GrantFiled: May 6, 2010Date of Patent: October 29, 2013Assignee: CSL LimitedInventors: Andrew Donald Nash, Manuel Baca, Louis Jerry Fabri, Dennis Zaller, William R. Strohl, Zhiqiang An
-
Patent number: 8540977Abstract: The present invention relates generally to the treatment of an interleukin-11 (IL-11)-mediated condition. More particularly, the present invention provides the use of modified forms of IL-11 which modulate IL-11 signaling in the treatment of IL-11-mediated conditions.Type: GrantFiled: July 25, 2011Date of Patent: September 24, 2013Assignee: CSL LimitedInventor: Manuel Baca
-
Publication number: 20130096058Abstract: The present invention provides Tenascin-3 FnIII domain-based multimeric scaffolds that specifically bind to TRAIL Receptor 2 (TRAIL R2), a cell membrane receptor involved in apoptosis. The invention further provides engineered variants with increased affinity for the target, increased stability, and reduced immunogenicity. Furthermore, the present invention is related to engineered multivalent scaffolds as prophylactic, diagnostic, or therapeutic agents, and their uses against diseases caused by cells expressing TRAIL R2, in particular to a therapeutic use against cancer.Type: ApplicationFiled: April 12, 2011Publication date: April 18, 2013Applicant: MedImmune, LLCInventors: Manuel Baca, Thomas Thisted, Jeffrey Swers, David Tice
-
Publication number: 20130079280Abstract: The present invention provides fibronectin type III (Fn3)-based multimeric scaffolds that specifically bind to one or more specific target antigen. The invention further provides bispecific Fn3-derived binding molecules that bind to two or more target antigens simultaneously, fusions, conjugates, and methods to increase the stability of Fn3-based binding molecules. Furthermore, the present invention is related to a prophylactic, therapeutic or diagnostic agent, which contains Fn3-based multimeric scaffolds.Type: ApplicationFiled: April 12, 2011Publication date: March 28, 2013Applicant: Medlmmune, LLCInventors: Manuel Baca, Thomas Thisted, Jeffrey Swers
-
Publication number: 20120321630Abstract: The present disclosure provides proteins comprising antigen binding domains of antibodies that bind to human granulocyte-colony stimulating factor receptor.Type: ApplicationFiled: June 13, 2012Publication date: December 20, 2012Applicant: CSL LIMITEDInventors: Andrew Donald NASH, Arna Elizabeth ANDREWS, Manuel BACA, Kirsten Mae EDWARDS, Matthew Philip HARDY, Con PANOUSIS, Felicity Meredith DUNLOP
-
Patent number: 8299027Abstract: The present invention relates generally to a method for modulating cell survival. Modulation of cell survival includes inducing, enhancing or otherwise promoting cell survival such as the survival of neural cells as well as facilitating cell death such as the death of targeted cancer cells. The modulation of cell survival is mediated by a region identified on the p75 neurotrophin receptor (p75NTR) required for death signalling. The present invention further provides genetic molecules which encode the death signalling region of p75NTR which are useful in antagonising death signal function as well as promoting cell death when expressed in targeted cells. The present invention also contemplates recombinant peptides, polypeptides and proteins as well as chemical equivalents, derivatives and homologues thereof which comprise the death signalling portion of p75NTR. Particularly useful molecules of the present invention comprise peptides corresponding to soluble forms of the death signalling portion of p75NTR.Type: GrantFiled: September 17, 2010Date of Patent: October 30, 2012Assignee: The University of QueenslandInventors: Perry Francis Bartlett, Elizabeth Jane Coulson, Katrina Fieldew, Manuel Baca, Trevor Kilpatrick, Cheema Surindar
-
Patent number: 8221755Abstract: The present invention relates generally to antibodies that bind to the Interleukin-13 receptor.alpha.1 chain (IL-13R.alpha.1) and antagonize IL-13 receptor-mediated signaling by IL-13 and/or IL-4. More particularly, the present invention provides humanized or human antibodies to mammalian and in particular IL-13R.alpha.1. These antibodies have uses in the treatment or prevention of IL-13- and/or IL-4-mediated diseases or conditions. The present invention further contemplates a method of modulating IL-13- and/or IL-4-mediated diseases or conditions by the administration of the subject antibodies. The present invention further provides an assay system useful for identifying antibodies or other agents which modulate IL-13 and/or IL-4 signaling through an IL-13 receptor complex. Accordingly, a method of screening for modulators of IL-13R.alpha.1/ligand interaction is also provided.Type: GrantFiled: July 1, 2010Date of Patent: July 17, 2012Assignee: Zenyth Operations Pty Ltd.Inventors: Felicity Meredith Dunlop, Manuel Baca, Andrew Donald Nash, Louis Jerry Fabri, Douglas James Hilton, Nicos A. Nicola
-
Patent number: 8182814Abstract: The present invention provides a method for the treatment or prophylaxis of T-helper type 2 (Th2)-mediated disorders using antagonists of IL-11.Type: GrantFiled: October 23, 2008Date of Patent: May 22, 2012Assignees: CSL Limited, Yale UniversityInventors: Manuel Baca, Andrew Donald Nash, Jack A. Elias
-
Publication number: 20110300100Abstract: The present invention relates generally to the treatment of an interleukin-11 (IL-11)-mediated condition. More particularly, the present invention provides the use of modified forms of IL-11 which modulate IL-11 signaling in the treatment of IL-11-mediated conditions.Type: ApplicationFiled: July 25, 2011Publication date: December 8, 2011Applicant: CSL LIMITEDInventor: Manuel BACA
-
Patent number: 7993637Abstract: The present invention relates generally to the treatment of an interleukin-11 (IL-11)-mediated condition. More particularly, the present invention provides the use of modified forms of IL-11 which modulate IL-11 signaling in the treatment of IL-11-mediated conditions.Type: GrantFiled: October 24, 2008Date of Patent: August 9, 2011Assignee: CSL LimitedInventor: Manuel Baca
-
Publication number: 20110172143Abstract: The present invention relates generally to a method for modulating cell survival. Modulation of cell survival includes inducing, enhancing or otherwise promoting cell survival such as the survival of neural cells as well as facilitating cell death such as the death of targeted cancer cells. The modulation of cell survival is mediated by a region identified on the p75 neurotrophin receptor (p75NTR) required for death signalling. The present invention further provides genetic molecules which encode the death signalling region of p75NTR which are useful in antagonising death signal function as well as promoting cell death when expressed in targeted cells. The present invention also contemplates recombinant peptides, polypeptides and proteins as well as chemical equivalents, derivatives and homologues thereof which comprise the death signalling portion of p75NTR. Particularly useful molecules of the present invention comprise peptides corresponding to soluble forms of the death signalling portion of p75NTR.Type: ApplicationFiled: September 17, 2010Publication date: July 14, 2011Applicant: University of Queensland, TheInventors: Perry Francis Bartlett, Elizabeth Jane Coulson, Katrina Fieldew, Manuel Baca, Trevor Kilpatrick, Cheema Surindar
-
Publication number: 20110081342Abstract: Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo.Type: ApplicationFiled: December 7, 2010Publication date: April 7, 2011Applicant: GENENTECH, INC.Inventors: MANUEL BACA, JAMES A. WELLS, LEONARD G. PRESTA, HENRY B. LOWMAN, YVONNE MAN-YEE CHEN
-
Patent number: 7919471Abstract: The present invention relates generally to a method for modulating cell survival. Modulation of cell survival includes inducing, enhancing or otherwise promoting cell survival such as the survival of neural cells as well as facilitating cell death such as the death of targeted cancer cells. The modulation of cell survival is mediated by a region identified on the p75 neurotrophin receptor (p75NTR) required for death signalling. The present invention further provides genetic molecules which encode the death signalling region of p75NTR which are useful in antagonising death signal function as well as promoting cell death when expressed in targeted cells. The present invention also contemplates recombinant peptides, polypeptides and proteins s well as chemical equivalents, derivatives and homologues thereof which comprise the death signalling portion of p75NTR. Particularly useful molecules of the present invention comprise peptides corresponding to soluble forms of the death signalling portion of p75NTR.Type: GrantFiled: August 18, 2004Date of Patent: April 5, 2011Assignee: The University of QueenslandInventors: Perry Francis Bartlett, Elizabeth Jane Coulson, Katrina Fieldew, Manuel Baca, Trevor Kilpatrick, Cheema Surindar
-
Publication number: 20110052575Abstract: Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo.Type: ApplicationFiled: April 27, 2010Publication date: March 3, 2011Applicant: Genentech, Inc.Inventors: Manuel Baca, James A. Wells, Leonard G. Presta, Henry B. Lowman, Yvonne Man-yee Chen
-
Publication number: 20110052597Abstract: Antibody antagonists of human interleukin-13 receptor alpha 1 which bind to hIL-13R?1 through domain 3 of the extracellular region of the receptor and inhibit IL-13 receptor-mediated signaling by IL-13 are disclosed herein. These antibodies have uses inter alia in the treatment or prevention of IL-13-related disorders and diseases. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing hIL-13R?1-mediated activities are also disclosed.Type: ApplicationFiled: October 19, 2007Publication date: March 3, 2011Inventors: Andrew Donald Nash, Manuel Baca, Louis Jerry Fabri, Dennis Zaller, William R. Strohl, Zhiqiang An
-
Publication number: 20110020363Abstract: The present invention relates generally to antibodies that bind to the Interleukin-13 receptor.alpha.1 chain (IL-13R.alpha.1) and antagonize IL-13 receptor-mediated signaling by IL-13 and/or IL-4. More particularly, the present invention provides humanized or human antibodies to mammalian and in particular IL-13R.alpha.1. These antibodies have uses in the treatment or prevention of IL-13- and/or IL-4-mediated diseases or conditions. The present invention further contemplates a method of modulating IL-13- and/or IL-4-mediated diseases or conditions by the administration of the subject antibodies. The present invention further provides an assay system useful for identifying antibodies or other agents which modulate IL-13 and/or IL-4 signaling through an IL-13 receptor complex. Accordingly, a method of screening for modulators of IL-13R.alpha.1/ligand interaction is also provided.Type: ApplicationFiled: July 1, 2010Publication date: January 27, 2011Applicant: ZENYTH OPERATIONS PTY LTD.Inventors: Felicity Meredith DUNLOP, Manuel BACA, Andrew Donald NASH, Louis Jerry FABRI, Douglas James HILTON, Nicos A. NICOLA
-
Publication number: 20100298541Abstract: The invention provides protein scaffolds and methods of preparing, screening, engineering and using such protein scaffolds.Type: ApplicationFiled: October 31, 2008Publication date: November 25, 2010Applicant: MEDIMMUNE, LLCInventors: Herren Wu, Manuel Baca, Jeffrey Swers, Benoy Chacko
-
Publication number: 20100285035Abstract: High affinity antibody antagonists of human interleukin-13 receptor alpha 1 are disclosed. The antibody molecules are effective in the inhibition of IL-13R?1-mediated activities and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with hIL-13R?1 activity. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing IL-13R?1-mediated activities are also disclosed.Type: ApplicationFiled: May 6, 2010Publication date: November 11, 2010Inventors: Andrew Donald Nash, Manuel Baca, Louis Jerry Fabri, Dennis Zaller, William R. Strohl, Zhiqiang An
-
Patent number: 7785590Abstract: The present invention relates generally to antibodies that bind to the Interleukin-13 receptor ?1 chain (IL-13R?1) and antagonize IL-13 receptor-mediated signaling by IL-13 and/or IL-4. More particularly, the present invention provides humanized or human antibodies to mammalian and in particular IL-13R?1. These antibodies have uses in the treatment or prevention of IL-13- and/or IL-4-mediated diseases or conditions. The present invention further contemplates a method of modulating IL-13- and/or IL-4-mediated diseases or conditions by the administration of the subject antibodies. The present invention further provides an assay system useful for identifying antibodies or other agents which modulate IL-13 and/or IL-4 signaling through an IL-13 receptor complex. Accordingly, a method of screening for modulators of IL-13R?1/ligand interaction is also provided.Type: GrantFiled: May 20, 2004Date of Patent: August 31, 2010Assignee: Zenyth Operations Pty Ltd.Inventors: Felicity Meredith Dunlop, Manuel Baca, Andrew Donald Nash, Louis Jerry Fabri, Douglas James Hilton, Nicos A Nicola